Document Detail


Ranibizumab therapy for choroidal neovascularisation secondary to non-age related macular degeneration causes.
MedLine Citation:
PMID:  22004186     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Background:  To investigate the efficacy of ranibizumab therapy for choroidal neovascular membranes (CNV) secondary to conditions other than macular degeneration. Design:  Prospective case series conducted at the Royal Victorian Eye and Ear Hospital. Participants:  Twelve month follow-up data for 41 patients with CNV recruited from the outpatient clinic from May 2008 to April 2010 is presented. Fifteen patients had myopia, 7 multifocal choroiditis (MFC) and 8 had other primary causes. Methods:  All patients had visual acuity, fluorescein angiogram and OCT performed at the initial visit (baseline). Ranibizumab was injected with a standard sterile technique. Patients were reviewed after one month and further injections were given at the treating doctors' discretion. Main Outcome Measures:  Change in visual acuity (VA) and central macular thickness (CMT) at 12 months compared to baseline for each of the groups. Local and systemic adverse outcomes were recorded. Results:  Analysis was stratified by primary pathology. On average, 40%, 43% and 25% of patients with myopia, multifocal choroiditis and "other" pathologies, respectively, experienced a 3 or more line improvement in vision. The average number of injections in 12 months was 4.2 for the entire group. CMT significantly decreased in the 12 month period for the combined group (p = 0.03). No patient had an adverse systemic side effect, however, there was one case of endophthalmitis. Conclusions:  Ranibizumab is an effective treatment for CNV secondary to non-AMD causes, with most patients gaining an improvement in the first 2 months following injection.
Authors:
Robyn Troutbeck; Roland Bunting; Anton van Heerdon; Melinda Cain; Robyn Guymer
Related Documents :
21641196 - The influence of flutter(®)vrp1 components on mucus transport of patients with bronchi...
21675956 - Safety of vascular endothelial and hepatocyte growth factor gene therapy in patients wi...
21563916 - Striving for euthyroidism in radioiodine therapy of graves' disease: a 12-year prospect...
6863076 - Ependymomas of the spinal cord.
7964806 - Reappraisal of rasmussen's syndrome with special emphasis on treatment with high doses ...
21850576 - Vascular calcification estimated by aortic calcification area index is a significant pr...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-10-17
Journal Detail:
Title:  Clinical & experimental ophthalmology     Volume:  -     ISSN:  1442-9071     ISO Abbreviation:  -     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-10-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100896531     Medline TA:  Clin Experiment Ophthalmol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2011 The Authors. Journal compilation © 2011 Royal Australian and New Zealand College of Ophthalmologists.
Affiliation:
Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Preventing alcohol misuse in young people aged 9-11 years through promoting family communication: an...
Next Document:  Chemical Modifications of Alginates in Organic Solvent Systems.